{
  "first_published_at": "2008-02-01", 
  "original_url": "http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON084741", 
  "title": "Herbal safety news: OSAS (intensive body lotion with aloe vera) found to contain steroids", 
  "tags": "{\"parsed_therapeutic\": [\"dermatology\"], \"Audience:\": [\"Primary care\", \"Secondary care\"], \"Therapeutic area:\": [\"Dermatology\"]}", 
  "_document_number": 299, 
  "label": null, 
  "icon": "http://www.mhra.gov.uk/home/images/MHRALook/img/dsu/adverse_icon.png", 
  "therapeutic_area": [
    "dermatology"
  ], 
  "raw_html": "<div id=\"dsuArticleContent\">\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\t<h1><a name=\"maincontent\" id=\"maincontent\"></a>Herbal safety news: OSAS (intensive body lotion with aloe vera) found to contain steroids</h1>\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<span class=\"ref\">Article date: February 2008</span> \r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element21)-->\r\n\t\t\t\t\t\t\t\t<!--The MHRA has recently found that samples of OSAS (intensive body lotion with aloe vera), an unlicensed product, have tested positive for variable amounts of the corticosteroid betamethasone.-->\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element21)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element22)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element22)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element13)-->\r\n\t\t\t\t\t\t\t\t<!--<p>The MHRA has recently found that samples of OSAS (intensive body lotion with aloe vera), an unlicensed product, have tested positive for variable amounts of the corticosteroid betamethasone.</p><p>Corticosteroids are used to treat inflammatory skin conditions, especially eczema and psoriasis. Long-term use can cause skin thinning and can worsen conditions such as eczema and dermatitis.</p><p>OSAS lotions have been supplied over the internet and from various Asian and African beauty shops for the treatment of eczema and psoriasis.</p><p>The lotion was brought to the attention of the MHRA by a paediatric dermatologist, who became concerned when the parent of a baby he was treating for eczema started to use this product on the infant.</p><p>We strongly advise that anyone who is using this product, particularly on young children and babies, should stop immediately. Discontinuation of the product may cause a rebound effect (ie, worsening of the condition) and patients should therefore consult a healthcare provider about alternative treatments.</p><p>&nbsp;</p><p><em>Article citation: Drug Safety Update Feb 2008; Vol 1, Issue 7: 9</em></p>-->\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element13)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!-- SS_BEGIN_SNIPPET(fragment7,1)-->\r\n\t\t\t\t\t\t\t\t<!-- call include to dynamically insert alt attributes into image tags within a wysiwyg element -->\r\n<!-- get a reference to the wysiwyg content -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n\t<p>The MHRA has recently found that samples of OSAS (intensive body lotion with aloe vera), an unlicensed product, have tested positive for variable amounts of the corticosteroid betamethasone.</p><p>Corticosteroids are used to treat inflammatory skin conditions, especially eczema and psoriasis. Long-term use can cause skin thinning and can worsen conditions such as eczema and dermatitis.</p><p>OSAS lotions have been supplied over the internet and from various Asian and African beauty shops for the treatment of eczema and psoriasis.</p><p>The lotion was brought to the attention of the MHRA by a paediatric dermatologist, who became concerned when the parent of a baby he was treating for eczema started to use this product on the infant.</p><p>We strongly advise that anyone who is using this product, particularly on young children and babies, should stop immediately. Discontinuation of the product may cause a rebound effect (ie, worsening of the condition) and patients should therefore consult a healthcare provider about alternative treatments.</p><p>&#160;</p><p><em>Article citation: Drug Safety Update Feb 2008; Vol 1, Issue 7: 9</em></p>\r\n\t\t\t\r\n\t\t\t\t\t\t\t\t<!-- SS_END_SNIPPET(fragment7,1)-->\r\n\t\t\t\t\t\t\t</div>\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t", 
  "date_of_article": "2008-02-01", 
  "date_last_modified": "2010-08-12", 
  "_assets": [], 
  "_item_id": 299, 
  "summary": "", 
  "body": "Article date: February 2008\n\nThe MHRA has recently found that samples of OSAS (intensive body lotion with aloe vera), an unlicensed product, have tested positive for variable amounts of the corticosteroid betamethasone.\n\nCorticosteroids are used to treat inflammatory skin conditions, especially eczema and psoriasis. Long-term use can cause skin thinning and can worsen conditions such as eczema and dermatitis.\n\nOSAS lotions have been supplied over the internet and from various Asian and African beauty shops for the treatment of eczema and psoriasis.\n\nThe lotion was brought to the attention of the MHRA by a paediatric dermatologist, who became concerned when the parent of a baby he was treating for eczema started to use this product on the infant.\n\nWe strongly advise that anyone who is using this product, particularly on young children and babies, should stop immediately. Discontinuation of the product may cause a rebound effect (ie, worsening of the condition) and patients should therefore consult a healthcare provider about alternative treatments.\n\nÂ \n\nArticle citation: Drug Safety Update Feb 2008; Vol 1, Issue 7: 9\n"
}